ES2189964T3 - Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih. - Google Patents

Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.

Info

Publication number
ES2189964T3
ES2189964T3 ES97928262T ES97928262T ES2189964T3 ES 2189964 T3 ES2189964 T3 ES 2189964T3 ES 97928262 T ES97928262 T ES 97928262T ES 97928262 T ES97928262 T ES 97928262T ES 2189964 T3 ES2189964 T3 ES 2189964T3
Authority
ES
Spain
Prior art keywords
combinations
zidovudina
treatment
hiv
hiv infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97928262T
Other languages
English (en)
Inventor
David Walter Barry
Clair Martha Heider St
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614024.9A external-priority patent/GB9614024D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2189964T3 publication Critical patent/ES2189964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMBINACIONES TERAPEUTICAS DE ACIDO [3R * (1R * , 2S * )]-[3-[[(4-AMINOFENIL)SULF ONIL](2METILPROPIL)-AMINO]-2-HIDROXI-1-FENILMETIL)PROPIL] CARBAMICO, ESTER DE TETRAHIDRO-3-FURANILO (141W94), 3''-AZIDO-3''DEOXITIOMIDINA (ZIDOVUDINA) Y (1S, 4R)-CIS-4-[2-AMINO6(CICLOPROPILAMINO)-9H-PURIN-9-YL]-2-CICLOPENTENO-1-METANOL (1592U89) QUE TIENEN ACTIVIDAD ANTI-VIH. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LAS COMBINACIONES Y A SU USO EN EL TRATAMIENTO DE INFECCIONES POR VIH INCLUYENDO LAS INFECCIONES CON MUTANTES DEL VIH QUE OFRECEN RESISTENCIA A INHIBIDORES NUCLEOSIDOS Y/O NO NUCLEOSIDOS.
ES97928262T 1996-06-25 1997-06-23 Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih. Expired - Lifetime ES2189964T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2217896P 1996-06-25 1996-06-25
GBGB9614024.9A GB9614024D0 (en) 1996-07-04 1996-07-04 Antiviral therapeutic combinations

Publications (1)

Publication Number Publication Date
ES2189964T3 true ES2189964T3 (es) 2003-07-16

Family

ID=26309631

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97928262T Expired - Lifetime ES2189964T3 (es) 1996-06-25 1997-06-23 Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.

Country Status (26)

Country Link
US (1) US6486136B1 (es)
EP (1) EP0910386B1 (es)
KR (1) KR20000022225A (es)
CN (1) CN1306430A (es)
AP (1) AP9801418A0 (es)
AT (1) ATE230267T1 (es)
AU (1) AU723877C (es)
BR (1) BR9709951A (es)
CA (1) CA2262765A1 (es)
CO (1) CO4910137A1 (es)
CZ (1) CZ429398A3 (es)
DE (1) DE69718168T2 (es)
EA (1) EA001457B1 (es)
ES (1) ES2189964T3 (es)
HU (1) HUP9903098A3 (es)
ID (1) ID18739A (es)
IL (1) IL127350A0 (es)
IS (1) IS4913A (es)
NO (1) NO986035L (es)
NZ (1) NZ333098A (es)
PE (1) PE87398A1 (es)
PL (1) PL330791A1 (es)
TR (1) TR199802703T2 (es)
WO (1) WO1997049410A1 (es)
YU (1) YU58498A (es)
ZA (1) ZA975565B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
BR9809124A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
WO1999066936A1 (en) * 1998-06-24 1999-12-29 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV

Also Published As

Publication number Publication date
CN1306430A (zh) 2001-08-01
AU3262697A (en) 1998-01-14
AU723877C (en) 2001-08-23
ID18739A (id) 1998-05-07
WO1997049410A1 (en) 1997-12-31
CZ429398A3 (cs) 1999-05-12
ZA975565B (en) 1998-12-23
HUP9903098A2 (hu) 1999-12-28
NO986035D0 (no) 1998-12-22
HUP9903098A3 (en) 2000-01-28
AU723877B2 (en) 2000-09-07
CA2262765A1 (en) 1997-12-31
HU9903098D0 (en) 1999-10-28
EP0910386B1 (en) 2003-01-02
EA199801046A1 (ru) 1999-08-26
AP9801418A0 (en) 1998-12-31
EP0910386A1 (en) 1999-04-28
DE69718168T2 (de) 2003-10-23
NO986035L (no) 1999-02-23
KR20000022225A (ko) 2000-04-25
PL330791A1 (en) 1999-06-07
NZ333098A (en) 2000-08-25
EA001457B1 (ru) 2001-04-23
ATE230267T1 (de) 2003-01-15
BR9709951A (pt) 1999-08-10
DE69718168D1 (de) 2003-02-06
YU58498A (en) 1999-11-22
CO4910137A1 (es) 2000-04-24
TR199802703T2 (xx) 1999-03-22
PE87398A1 (es) 1999-01-15
IL127350A0 (en) 1999-10-28
IS4913A (is) 1998-11-30
US6486136B1 (en) 2002-11-26

Similar Documents

Publication Publication Date Title
MY115461A (en) Synergistic combinations of zidovudine, 1592u89 and 3tc
ES2377066T3 (es) Composición terapéutica que contiene al menos un derivado de la pirrobenzodiacepina y la fludarabina
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
ES2145118T3 (es) Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
NO986034L (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV
ES2189964T3 (es) Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
ES2165948T3 (es) Modificacion cristalina termoestable y apta para almacenaje de n-metil-n-((1s)-1-fenil-2-((3s)-3-hidroxi-pirrolidin-1-il)-etil)-2,2-difenil-acetamida, y procedimiento para su obtencion.
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
BR9810072A (pt) Formulação farmacêutica semi-sólida contendo dexcetoprofen trometamol
AR022462A1 (es) Uso de un agente que disminuye el colesterol
AR005551A1 (es) Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple
BR0210063A (pt) Composição estável e uso da mesma
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
AR007615A1 (es) Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene.
WO2000018384A3 (en) Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
AR008764A1 (es) Sales hidratadas de n,n'-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
RU93004467A (ru) Замещенные пуриновые арабинозы, их применение, фармацевтическая композиция
AR007616A1 (es) Combinaciones antivirales
TH34798A (th) การรวมสารต้านไวรัส
TH34652A (th) การรวมสารต้านไวรัส
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
BR9812265A (pt) Uso de análogos de gaba, tais como gabapentina, na fabricação de um medicamento para o tratamento de doenças inflamatórias.